InflaRx Surges 25% on Intraday Rally—What’s Fueling the Biotech Breakout?

Summary
• InflaRx (IFRX) rockets 25% to $1.25, surging past 52-week high of $2.815
• Biotech sector buzzes over FDA’s noninvasive liver trial endpoint proposal
• RSI hits 79.7, signaling overbought territory amid volatile intraday swing
• Turnover jumps 2.19% as $1.29 high clashes with $0.985 low

Biotech stocks are in a tailwind as InflaRx defies its long-term bearish trend with a jaw-dropping 25% intraday surge. The move coincides with the FDA’s rumored shift in liver disease trial endpoints, sparking sector-wide optimism. With technicals flashing overbought signals and a 52-week high still in reach, the question is: Is this a breakout or a flash crash?

FDA’s Liver Trial Endpoint Shift Ignites Biotech Optimism
The FDA’s consideration of noninvasive diagnostic measures for fatty liver disease has sent shockwaves through the biotech sector. While InflaRx has no direct ties to liver disease, the broader regulatory shift signals accelerated drug development timelines—a narrative investors are extrapolating to all biotech innovators. The 25% surge aligns with sector-wide speculation that streamlined endpoints could reduce R&D costs and fast-track approvals, creating a tailwind for speculative biotech plays.

Biotech Sector Splits as InflaRx Defies AMGN’s Slide
While InflaRx soars, sector leader Amgen (AMGN) declines 0.86%, highlighting divergent investor sentiment. The FDA’s liver trial news has polarized the sector: innovators like InflaRx benefit from speculative momentum, while established players like Amgen face pressure from profit-taking. This split underscores a shift in risk appetite, with traders favoring high-growth biotechs over mature peers.

Technical Overbought Signals Demand Caution—Here’s How to Play the Volatility
• RSI: 79.7 (overbought)
• MACD Histogram: 0.0149 (bullish divergence)
• Bollinger Bands: $0.7765–$0.9726 (price at upper band)
• 200D MA: $1.5176 (price below long-term trend)

Technical indicators paint a mixed picture: RSI suggests imminent pullback, while MACD hints at short-term bullish momentum. The 52-week high of $2.815 remains a distant target, but the 200-day average acts as a formidable resistance. With no options data available, leveraged ETFs are off the table. Traders should monitor the $1.25 level—break above triggers a test of $1.29, while a retest of $0.985 could reignite bearish sentiment.

Backtest InflaRx Stock Performance
Query limit exceeded.

Biotech’s Regulatory Windfall—Act Now Before the FDA’s Next Move
InflaRx’s 25% surge is a microcosm of the biotech sector’s regulatory-driven volatility. While the FDA’s liver trial shift offers a near-term catalyst, the stock’s long-term bearish trend and overbought RSI demand caution. Watch Amgen’s -0.86% decline as a barometer of sector sentiment. For now, position for a breakout above $1.25 or a sharp correction to $0.985. Act swiftly—regulatory clarity could reshape the sector before the week’s end.